Protalix BioTherapeutics (PLX) Receivables (2010 - 2026)

Protalix BioTherapeutics has reported Receivables for 17 years, with the latest figure at $16.5 million in Q2 2026.

• On a quarterly basis, Receivables rose 74.76% year-over-year to $16.5 million in Q2 2026; TTM through Jun 2026 was $16.5 million, a 74.76% increase from a year earlier, with the FY2025 full-year figure at $8.8 million, up 203.88% from the prior year.
• Receivables was $16.5 million for Q2 2026 at Protalix BioTherapeutics, up from $2.9 million in the prior quarter.
• The five-year high for Receivables was $16.5 million in Q2 2026, with the low at $1.3 million in Q1 2023.
• Average Receivables over 5 years is $6.5 million, with a median of $5.0 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2025: Receivables sank 77.93% in 2023, then soared 557.18% in 2025.
• Over 5 years, Receivables stood at $4.6 million in 2022, then rose by 14.96% to $5.3 million in 2023, then sank by 44.82% to $2.9 million in 2024, then soared by 203.88% to $8.8 million in 2025, then surged by 86.69% to $16.5 million in 2026.
• The last three Receivables figures came in at $16.5 million (Q2 2026), $2.9 million (Q1 2026), and $8.8 million (Q4 2025), per Business Quant data.